Reply to M. Voskoboynik et al

J Clin Oncol. 2014 Oct 1;32(28):3199-200. doi: 10.1200/JCO.2014.56.5762. Epub 2014 Jul 28.

Authors

David M Hyman¹, Anne A Eaton², Mrinal M Gounder³, S Percy Ivy⁴, Alexia Iasonos², David R Spriggs²

Affiliations

¹ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY hymand@mskcc.org.
² Memorial Sloan Kettering Cancer Center, New York, NY.
³ Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY.
⁴ The National Cancer Institute, Bethesda, MD.

PMID: 25071117
DOI: 10.1200/JCO.2014.56.5762

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects*
Clinical Trials, Phase I as Topic / methods*
Humans
Nomograms*

Substances

Antineoplastic Agents

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States